Want to see AU:PIQ full AI Analyst Report?
PIQ Stock Chart & Stats
AU$0.16
<AU$0.01(3.23%)
At close: 4:00 PM EDT
AU$0.16
<AU$0.01(3.23%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.86
Previous CloseN/A
Volume311.76K
Average Volume (3M)105.74K
Market Cap
AU$24.81M
Enterprise ValueAU$99.81
Total Cash (Recent Filing)AU$7.67M
Total Debt (Recent Filing)AU$681.45K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Feb 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding165,373,120
10 Day Avg. Volume56,474
30 Day Avg. Volume105,736
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)3.26
Price to Sales (P/S)67.98
P/FCF Ratio-2.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$5.90M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage reduces fixed financial obligations and preserves balance-sheet flexibility compared with a heavily debt-funded business. This gives Proteomics International more room to allocate capital toward diagnostic development and laboratory operations while limiting the direct impact of interest and refinancing pressure.
Diversified Operating ModelCombining proprietary diagnostic development with contract laboratory services creates more than one route to commercial activity. The mix can support customer diversification and provide an established services platform alongside longer-term opportunities to commercialize proteomics-based tests.
Specialized Proteomics CapabilityA focused capability in proteomics-based testing and specialty analytical services provides a distinct technical identity within precision diagnostics. Specialized expertise may support repeat customer relationships and create a foundation for developing additional blood-based tests over the medium term.
Bears Say
Sharp Revenue ContractionThe sharp 2026 revenue decline interrupts the earlier modest growth trend and raises concern about the durability of customer demand or commercialization progress. Lower revenue reduces operating leverage, limits reinvestment capacity, and makes a near-term path to sustainable profitability more difficult.
Deepening UnprofitabilityPersistent losses across the reported period indicate that the current business model is not yet converting activity into sustainable earnings. The 2026 negative gross profit and larger operating loss are especially adverse because they suggest costs are not scaling with revenue, increasing execution pressure.
Persistent Cash BurnRecurring negative operating and free cash flow means the business is consuming cash rather than funding operations internally. Continued burn can increase reliance on external funding, constrain investment in diagnostic development, and heighten financial risk if losses persist over coming quarters.
Proteomics International Laboratories Ltd. News
PIQ FAQ
What was Proteomics International Laboratories Ltd.’s price range in the past 12 months?
Proteomics International Laboratories Ltd. lowest share price was AU$0.10 and its highest was AU$0.86 in the past 12 months.
What is Proteomics International Laboratories Ltd.’s market cap?
Proteomics International Laboratories Ltd.’s market cap is AU$24.81M.
When is Proteomics International Laboratories Ltd.’s upcoming earnings report date?
Proteomics International Laboratories Ltd.’s upcoming earnings report date is Feb 25, 2027 which is in 171 days.
How were Proteomics International Laboratories Ltd.’s earnings last quarter?
Proteomics International Laboratories Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.04 earnings per share for the quarter.
Is Proteomics International Laboratories Ltd. overvalued?
According to Wall Street analysts Proteomics International Laboratories Ltd.’s price is currently Overvalued.
Does Proteomics International Laboratories Ltd. pay dividends?
Proteomics International Laboratories Ltd. does not currently pay dividends.
What is Proteomics International Laboratories Ltd.’s EPS estimate?
Proteomics International Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteomics International Laboratories Ltd. have?
Proteomics International Laboratories Ltd. has 165,373,120 shares outstanding.
What happened to Proteomics International Laboratories Ltd.’s price movement after its last earnings report?
Proteomics International Laboratories Ltd. reported an EPS of -AU$0.04 in its last earnings report. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Proteomics International Laboratories Ltd.?
Currently, no hedge funds are holding shares in AU:PIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Proteomics International Laboratories Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.94%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.
Technical Analysis
Telix Pharmaceuticals
―
Vectus Biosystems Limited
―
AnteoTech Ltd
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―